Human endothelin-1 clearance kinetics revealed by a radiotracer technique.
نویسندگان
چکیده
Levels of endothelin-1 (ET-1) are elevated in many disease states, although its total body kinetics of elimination are poorly understood. Therefore, it remains uncertain whether the presence of elevated levels of ET-1 in the setting of disease are secondary to changes in production or clearance or some combination thereof. Using a 125I-labeled ET-1 infusion technique, the volume of distribution and kinetics of clearance of endothelin were described in five normal volunteers. Heart rate, blood pressure, right atrial pressure, and arterial blood samples for the counting of 125I and the measurement of ET-1 were obtained at multiple time points before and up to 45 h after the start of the infusion. The radiotracer infusion had no effect on heart rate, blood pressure, right atrial pressure, or endogenous ET-1 levels. ET-1 clearance was best described by a three-compartment model, which revealed that ET-1 has a much longer terminal half-life and volume of distribution than was previously reported. This suggests extensive uptake of ET-1 in various organ systems and slow clearance. These new findings have important implications for the understanding of the pathophysiology of ET-1 in disease states as well as for the understanding and development of ET-1 receptor blockers and endothelin-converting enzyme inhibitors.
منابع مشابه
Reduction in hepatic endothelin-1 clearance in cirrhosis.
Circulating endothelin-1 (ET-1) levels are increased in cirrhosis. The liver is an important site for circulating ET-1 clearance through the ET(B) receptor. We evaluated ET-1 kinetics in cirrhosis to determine if a reduced liver clearance contributes to this process. Cirrhosis was induced by carbon tetrachloride in rats. Hepatic ET-1 clearance was measured in isolated perfused livers using the ...
متن کاملIncreased endothelin-1 production in patients with chronic heart failure.
Endothelin-1 (ET-1) concentrations are elevated in patients with congestive heart failure (CHF), although the cause of this increase remains uncertain. We hypothesized that abnormalities in ET-1 production, clearance, or a combination of these may be the cause of elevated ET-1 concentrations in chronic CHF. The kinetics of clearance of ET-1 were measured with (125)I-labeled ET-1 in eight patien...
متن کاملبررسی کارآیی انسولین انسانی: استفاده از روش کلامپ با سطح ثابت قند خون برای مقایسه دو نوع مختلف تجاری انسولین انسانی
Background: The aim of this study was to compare time action profile of regular human Insulin produced by Exir pharmaceutical Co. and Actrapid® HM produced by Novo Nordisk with euglycemic clamp technique for the first time in Iran. Methods: Euglycemic glucose clamps were performed with two Insulin brands in a single-center, randomized, double-blind, and crossover study on 6 healthy male volunt...
متن کاملReduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction.
BACKGROUND The pulmonary vascular bed is a major site for endothelin-1 (ET-1) clearance. A reduced clearance could contribute to the increase in circulating ET-1 levels found in heart failure (HF). We therefore evaluated the effect of HF on pulmonary ET-1 clearance and on plasma ET-1 concentrations. METHODS AND RESULTS Rats with myocardial infarction (n=24) were compared with sham-operated ra...
متن کاملEffect of Endothelin-A Receptor Blockade on the Early Phase of Ischemia/Reperfusion-Induced Acute Renal Failure in Anesthetized Rats
Background: Previous studies have shown increases in endothelin (ET) concentration of plasma and renal tissues in acute renal failure (ARF). ET has a potent vasoconstrictor effect, through binding with its ETA receptors, and may play some roles in renal hemodynamic dysfunction in ARF.Objective: To examine the beneficial effect of a selective ETA-receptor antagonist on renal dysfunction and tis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of pharmacology and experimental therapeutics
دوره 289 1 شماره
صفحات -
تاریخ انتشار 1999